2021 Clinical Trials Epilepsy Media 
Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. 3 Nature Aging | VOL 1 | July 2021 | p.
Cannabis Law Report
OCTOBER 5, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. Media: media@mymd.com. ET on Benzinga’s live stream channel.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 22, 2021
Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Media Contact: media@mymd.com. About MyMD Pharmaceuticals, Inc. 646) 421-9523.
Project CBD
FEBRUARY 28, 2023
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.
Cannabis Law Report
JANUARY 20, 2022
ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Email: alexander.speiser@eleusisltd.com.
Cannabis Law Report
NOVEMBER 24, 2021
Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Conclusions. Background.
Cannabis Law Report
DECEMBER 28, 2021
.–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I Mack, Chairman and CEO of Virpax. to conduct this study in Canada.
Expert insights. Personalized for you.
52 
Let's personalize your content